Turkish Thoracic Journal
Original Article

A survey of physician’s knowledge, attitudes, and practices about idiopathic pulmonary fibrosis in Turkey


Department of Pulmonary Diseases, Gazi University, School of Medicine, Ankara, Turkey


Department of Pulmonary Diseases, İstanbul University, İstanbul School of Medicine, Istanbul, Turkey


Department of Pulmonary Diseases, Ondokuz Mayıs University, School of Medicine, Samsun, Turkey


Department of Pulmonary Diseases, Ankara University, School of Medicine, Ankara, Turkey


Department of Pulmonary Diseases, Pamukkale University, School of Medicine, Denizli, Turkey


Department of Pulmonary Diseases, İstanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, İstanbul, Turkey


Claude Bernard University, Reference Center for Rare Pulmonary Diseases, UMR754, Lyon, France

Turk Thorac J 0; 5: 0-0
DOI: 10.5152/TurkThoracJ.2019.180181
Read: 685 Downloads: 205 Published: 18 July 2019


Objective: The aim of this study is to determine the approaches of Turkish pulmonologists to the diagnosis and treatment of patients with idiopathic pulmonary fibrosis (IPF) in daily clinical practice.


Material and methods: A questionnaire containing 38 questions about IPF diagnosis and treatment was applied to pulmonologists between 22-29 January 2018 and data of 158 physicians who responded to the questionnaire were evaluated.


Results: Results of this survey showed that mean number of patients that physicians follow-up and managed annually was 8.3 and 5 respectively. The mean symptom duration of the patients before the diagnosis was 9-12 months. Patients have been seen by average three physicians prior to confirmed diagnosis. Almost 80% of the physicians have opportunity to access a pathologist and radiologist who are specialized in IPF. However only 26% of them have opportunity to access regular multidisciplinary meetings. Although the most commonly prescribed drugs were antifibrotics, approximately 10% of patients were prescribed steroids, N-acetylcysteine and immunosuppressive drugs. Most of the physicians (81%) were aware of international guidelines however Turkish Thoracic Society Idiopathic Pulmonary Fibrosis Diagnosis and Treatment Consensus Report was read by only 41% of them.



Conclusion: This survey may lead to IPF awareness in Turkey, and may help closing the gaps on diagnosis and treatment.


Cite this article as: Türktaş H, Okumuş G, Uzun O, et al. Diagnosis, management and attitudes about idiopathic pulmonary fibrosis among Turkish pulmonologists. Turk Thorac J 2019; DOI:10.5152/TurkThoracJ.2019.180181

EISSN 2149-2530